Sulodexide Treatment in Patients With Dense Deposit Disease

Inclusion Criteria: 1. Patients must be 5 yrs. to 20 yrs. old 2. Patients must have Membranoproliferative Glomerulonephritis Type II (MPGN2), also known as Dense Deposit Disease (DDD) Exclusion Criteria: 1. Patients less than 5 years of age or older than 20 years of age 2. Patients who DO NOT have a diagnosis of Membranoproliferative Glomerulonephritis (MPGN 2) also known as Dense Deposit Disease 3. Evidence of hepatic dysfunction including total bilirubin \>2.0mg/dL (34 micromol/L) or liver enzymes \>3 times upper limit of normal. 4. A history of any major medical condition (excluding DDD), including but not limited to: gastrointestinal bleeding in the past 3 months; HIV; active Hepatitis B or C (current active disease defined as an abnormal liver biopsy or persistent, elevated transaminases, SGOT, SGPT); and other medical conditions deemed serious by the investigator 5. any risk of bleeding, including a history of bleeding diathesis and a platelet count \<100,000/mm3 6. active cancer 7. Participation in any experimental drug study in the 60 days prior to entry into this study; or plan to participate in any experimental drug study during the study period. 8. Known allergy or intolerance to any heparin-like compounds 9. Inability to give an informed consent or cooperate with the study personnel -